Background/AimsThe widespread use of cytotoxic chemotherapy and immunosuppressants has resulted in reactivation of hepatitis B virus (HBV) recently becoming an issue. Although rituximab (an anti-CD20 monoclonal antibody) has revolutionized the treatment of lymphoma. recent reports have suggested that rituximab therapy increases the risk of viral-mediated complications. and particularl... https://www.roneverhart.com/